Point your AI agent at freehire and let it find you a job.

Get the CLI →

exelixis

Discovers and commercializes innovative medicines for cancer treatment.

H-1B sponsor history — This employer has had H-1B petitions approved by USCIS in the last five fiscal years, per the USCIS H-1B Employer Data Hub. The approval belongs to the employer and is not a commitment to sponsor this role.
Discussion
biotechhealthcarepharmaceuticals

Company facts

Founded
1994
Employees
1,147
Headquarters
United States
CEO
Michael M. Morrissey, Ph.D.
Type
Public
Listed
NASDAQ: EXEL

About

Exelixis, Inc. is an oncology-focused biotechnology company headquartered in Alameda, California, dedicated to the discovery, development, and commercialization of innovative treatments for cancer. Founded in 1994, Exelixis has established a robust portfolio of therapies designed to address the unmet medical needs of patients suffering from various forms of difficult-to-treat cancers. With a vision to shape the future of oncology, the company is committed to accelerating the pace of drug discovery and the advancement of clinical development programs. At Exelixis, cancer is viewed as a pivotal challenge that demands innovative solutions. The company leverages its expertise in biotherapeutics and small molecule discovery to create new treatments that not only aim to enhance the quality of life for patients but also strive for potential cures. Their flagship product, Cabozantinib (CABOMETYX®), has set a precedent for the company’s mission to deliver impactful cancer therapies. Beyond commercial success, Exelixis actively engages in various environmental, social, and governance initiatives to ensure that their mission extends to benefits for the wider community, showing commitment not only to their patients but also to creating a positive societal impact.

40 jobs

Tailor your CV for this role?

We couldn't check your fit for this role — add a CV to your profile to see it next time.

A new version of freehire is available